These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24116160)

  • 1. Co-overexpression of GEP100 and AMAP1 proteins correlates with rapid local recurrence after breast conservative therapy.
    Kinoshita R; Nam JM; Ito YM; Hatanaka KC; Hashimoto A; Handa H; Otsuka Y; Hashimoto S; Onodera Y; Hosoda M; Onodera S; Shimizu S; Tanaka S; Shirato H; Tanino M; Sabe H
    PLoS One; 2013; 8(10):e76791. PubMed ID: 24116160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
    Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
    Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
    Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
    PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
    Morishige M; Hashimoto S; Ogawa E; Toda Y; Kotani H; Hirose M; Wei S; Hashimoto A; Yamada A; Yano H; Mazaki Y; Kodama H; Nio Y; Manabe T; Wada H; Kobayashi H; Sabe H
    Nat Cell Biol; 2008 Jan; 10(1):85-92. PubMed ID: 18084281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EGFR-GEP100-Arf6 pathway in breast cancer: Full invasiveness is not from the inside.
    Sabe H; Hashimoto S; Morishige M; Hashimoto A; Ogawa E
    Cell Adh Migr; 2008; 2(2):71-3. PubMed ID: 19262097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients.
    Sato H; Hatanaka KC; Hatanaka Y; Hatakeyama H; Hashimoto A; Matsuno Y; Fukuda S; Sabe H
    Cell Commun Signal; 2014 Mar; 12():17. PubMed ID: 24621372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmastectomy breast reconstruction after previous lumpectomy and radiation therapy: analysis of complications and satisfaction.
    Khansa I; Colakoglu S; Curtis MS; Yueh JH; Ogunleye A; Tobias AM; Lee BT
    Ann Plast Surg; 2011 May; 66(5):444-51. PubMed ID: 21451371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Local recurrence based on size after conservative surgery in breast cancer stage T1-T2. A population-based study].
    Martínez-Ramos D; Fortea-Sanchis C; Escrig-Sos J; Prats-de Puig M; Queralt-Martín R; Salvador-Sanchis JL
    Cir Cir; 2014; 82(3):252-61. PubMed ID: 25238466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
    Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
    Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy (BCT)?
    Hafeez F; Neboori HJ; Harigopal M; Wu H; Haffty BG; Yang Q; Schiff D; Moran MS
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):344-8. PubMed ID: 23910708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients.
    Kreike B; Halfwerk H; Armstrong N; Bult P; Foekens JA; Veltkamp SC; Nuyten DS; Bartelink H; van de Vijver MJ
    Clin Cancer Res; 2009 Jun; 15(12):4181-90. PubMed ID: 19470741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
    Anderson SJ; Wapnir I; Dignam JJ; Fisher B; Mamounas EP; Jeong JH; Geyer CE; Wickerham DL; Costantino JP; Wolmark N
    J Clin Oncol; 2009 May; 27(15):2466-73. PubMed ID: 19349544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
    Yamazaki N; Wada N; Yamauchi C; Yoneyama K
    Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of isolated locoregional recurrence in patients with breast cancer according to their primary local treatment.
    Shenouda MN; Sadek BT; Goldberg SI; Keruakous AR; Croft BJ; Abi Raad RF; Taghian AG
    Clin Breast Cancer; 2014 Jun; 14(3):198-204. PubMed ID: 24485702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.